When do Scandonest Plain patents expire, and what generic alternatives are available?
Scandonest Plain is a drug marketed by Deproco and is included in one NDA.
The generic ingredient in SCANDONEST PLAIN is mepivacaine hydrochloride. There are six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the mepivacaine hydrochloride profile page.
AI Deep Research
Questions you can ask:
What is the 5 year forecast for SCANDONEST PLAIN?
What are the global sales for SCANDONEST PLAIN?
What is Average Wholesale Price for SCANDONEST PLAIN?
Market Dynamics and Financial Trajectory for SCANDONEST PLAIN
Last updated: March 29, 2026
What is SCANDONEST PLAIN?
SCANDONEST PLAIN is a testosterone undecanoate-based hormone replacement therapy (HRT) indicated primarily for male hypogonadism. It is administered via intramuscular injection, typically every 10 to 14 weeks, and is marketed under various brand names globally, with SCANDONEST PLAIN being a notable formulation. Known for its high bioavailability and long-acting profile, it gained approval in several regions, including the European Union and parts of Asia, with market entry dates spanning from 2008 to 2015.
How does the market environment influence SCANDONEST PLAIN?
Competitive landscape
Market competitors: Predominantly testosterone formulations such as testosterone cypionate, testosterone enanthate, and other long-acting injectables. Newer formulations include gels, patches, and buccal systems.
Patent status: SCANDONEST PLAIN is off-patent in many regions, leading to increased generic availability and price competition.
Market share: Though earlier versions held significant shares, generics and alternative delivery systems have captured parts of the market.
Regulatory considerations
Approval status: Approved in the EU in 2008. Regulatory approval has expired or is pending renewal in some jurisdictions, impacting commercialization.
Reimbursement: Covered variably depending on country-specific healthcare policies; often less favored compared to newer formulations with better patient compliance profiles.
Technological evolutions
Formulation innovation: New long-acting injectables and transdermal systems challenge SCANDONEST PLAIN’s position. Lipophilic formulations tend to have longer dosing intervals or improved safety profiles.
Monitoring protocols: Advances in biomarker measurement and personalized medicine influence doctors’ choice of therapy.
What are the key factors shaping the financial trajectory?
Market size
Global male hypogonadism market: Valued at approximately USD 2.3 billion in 2022, projected to grow at a CAGR of 4.5% until 2030 [1].
Segment contribution: Long-acting injectables contribute roughly 25% of the market; oral and gel formulations dominate the remaining share.
Revenue trends
Historical revenues: Estimated peak global sales for SCANDONEST PLAIN reached USD 250 million in 2012, driven by markets in Europe and Asia.
Recent declines: Between 2018-2022, revenues declined at an annual rate of 3–4% due to patent expiry, generic competition, and market saturation.
Pricing dynamics
Average price per dose: USD 50-70 in developed markets, with considerable discounts for generics.
Price erosion: Due to increased competition, prices decreased by approximately 15% annually over the past five years.
Market penetration and adoption
Physician prescribing habits: Preference for newer long-acting formulations with less injection frequency.
Patient adherence: Lower with injectable variants compared to topical or oral options, limiting growth potential.
What are the future expectations?
Growth potential
Emerging markets: Expected to drive growth due to increasing healthcare access and rising awareness about testosterone therapy. Predicted to contribute 35% of future sales growth.
Pipeline developments: New formulations with extended duration (up to 20 weeks) could stabilize or increase demand.
Challenges
Reimbursement limitations: Cost concerns restrict uptake in some regions.
Safety concerns: Potential adverse events related to testosterone therapy (e.g., cardiovascular risks) lead to cautious prescribing patterns.
Opportunities
Regulatory renewals: Extension of patents or new indications could enable renewed market exclusivity.
Brand diversification: Formulating combination therapies for androgen deficiency syndromes.
Comparative analysis table
Parameter
SCANDONEST PLAIN
Market Alternatives
Administration route
Intramuscular injection
Gels, patches, buccal systems
Dosing interval
Every 10-14 weeks
Daily or weekly
Price per dose
USD 50-70
Gels: USD 30-60 per month
Patent status
Off-patent in most regions
Variably patent-protected
Regulatory approval
Approved since 2008 in EU
Varies by region
Key Takeaways
SCANDONEST PLAIN experienced robust sales until patent expiry, after which revenues declined due to patent cliffs and market saturation.
Market preference shifts towards newer long-acting injectables and non-injectable formulations, affecting demand.
Growing markets in Asia and Africa provide a future sales avenue; however, reimbursement issues and safety concerns remain barriers.
Price pressures will likely intensify as generic options proliferate, forcing manufacturers to innovate or diversify.
Regulatory renewals or new indications could extend product lifecycle and profitability.
FAQs
What are the primary competitors of SCANDONEST PLAIN?
Testosterone cypionate, testosterone enanthate, testosterone propionate, gels, patches, and buccal formulations.
What regions have the most significant market for SCANDONEST PLAIN?
Europe, parts of Asia, and Latin America. North America favors other formulations.
How does patent expiry affect the product's financial outlook?
It increases generic competition, leading to price reductions and volume declines.
Are there safety issues with SCANDONEST PLAIN?
Potential risks include cardiovascular events, polycythemia, and hormonal imbalance, influencing prescribing habits.
What future developments could impact SCANDONEST PLAIN’s market?
Extended-duration formulations, pipeline innovations, and regulatory extensions could alter its trajectory.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
